The Chalcogen, X, Is In A -c(=x)- Group Patents (Class 548/253)
-
Publication number: 20090192140Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: ApplicationFiled: May 16, 2007Publication date: July 30, 2009Applicant: Aegera Therapeutics Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Publication number: 20090176841Abstract: An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is —CH2— or —CO—; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is —NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].Type: ApplicationFiled: December 23, 2008Publication date: July 9, 2009Applicant: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Yukiyasu Asano, Koji Maeda, Nobuaki Tsuruta, Toru Murase
-
Publication number: 20090170917Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.Type: ApplicationFiled: December 2, 2008Publication date: July 2, 2009Inventors: Seung-Yub Lee, Eduardo Perez, Keshava Rapole, Gopal Sarngadharan, Gregory B. Stock, Jeffry B. Stock, Maxwell Stock, Michael Voronkov, Peter Wolanin
-
Publication number: 20090170908Abstract: The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereofType: ApplicationFiled: October 24, 2008Publication date: July 2, 2009Applicant: Japan Tobacco Inc.Inventors: Takashi Shimada, Hiroshi Ueno, Kazuhiro Tsutsumi, Kouichi Aoyagi, Tomoyuki Manabe, Shin-Ya Sasaki, Susumu Katoh
-
Publication number: 20090163502Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.Type: ApplicationFiled: December 17, 2008Publication date: June 25, 2009Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
-
Publication number: 20090163560Abstract: A compound having a structure and therapeutic methods, compositions, and medicaments related thereto are disclosed herein.Type: ApplicationFiled: February 17, 2009Publication date: June 25, 2009Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090156585Abstract: A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.Type: ApplicationFiled: November 8, 2006Publication date: June 18, 2009Inventors: Lili Feng, Sven Erik Godtfredsen, Bin Hu, Yugang Liu, Piotr Karpinski, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Thomas J. Blacklock
-
Publication number: 20090149521Abstract: The invention relates to compounds having the formula: wherein Ar, r, n, X, R2, R2?, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.Type: ApplicationFiled: December 8, 2008Publication date: June 11, 2009Inventors: Seok-Ki Choi, Paul R. Fatheree, Robert Murray McKinnell, Brooke Olson
-
Publication number: 20090137648Abstract: The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-1-[(2?-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one hydrochloride, irbesartan hydrochloride, novel hydrated and anhydrous crystalline forms thereof, amorphous irbesartan hydrochloride, formulations containing the same, therapeutic uses thereof and methods of treatment employing the same. The process of the present invention is a one-pot process which comprises reacting intermediate compounds 2n-butyl-1,3-diazaspiro[4,4]non-1-en-4-one and 5-(4?-bromomethyl-biphenyl-2-yl)-1-trityl-1H-tetrazole.Type: ApplicationFiled: October 26, 2005Publication date: May 28, 2009Inventors: Pathi L. Srinivas, Jayamadhava P. Relekar, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
-
Publication number: 20090131492Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: ApplicationFiled: October 18, 2007Publication date: May 21, 2009Inventors: Sara S. Hadida Ruah, Peter D.J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Djamel Numa
-
Publication number: 20090131680Abstract: The present invention relates to an improved process for the manufacture of olmesartan and pharmaceutically acceptable salts and esters thereof as an active ingredient of a medicament for the treatment of hypertension and related diseases and conditions.Type: ApplicationFiled: July 27, 2006Publication date: May 21, 2009Applicant: KRKAInventors: Silvo Zupancic, Anica Pecavar, Miha Vrbinc, Renata Osolnik
-
Patent number: 7534894Abstract: The present invention relates generally to substituted biphenyloxy acids (such as 4?-aryl-amido-biphenyl-4(3)-yloxy-acids and 4?-aryl-amidomethyl-biphenyl-4(3)-yloxy-acids) and methods of using them, for example, as PAI-1 inhibitors.Type: GrantFiled: September 23, 2004Date of Patent: May 19, 2009Assignee: WyethInventors: Thomas Joseph Commons, Susan Christman Croce, Eugene John Trybulski, Hassan Mahmoud Elokdah, David LeRoy Crandall
-
Publication number: 20090117042Abstract: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.Type: ApplicationFiled: May 22, 2008Publication date: May 7, 2009Applicant: The Johns Hopkins UniversityInventors: Martin Gilbert Pomper, Jiazhong Zhang, Alan P. Kozikowski, John L. Musachio
-
Patent number: 7528258Abstract: The present invention provides a process for preparing olmesartan medoxomil.Type: GrantFiled: September 2, 2005Date of Patent: May 5, 2009Assignee: Teva Pharmaceutical Industries LtdInventors: Lilach Hedvati, Gideon Pilarsky
-
Publication number: 20090111730Abstract: Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere.Type: ApplicationFiled: June 21, 2005Publication date: April 30, 2009Applicant: Novo Nordisk A/SInventors: Florencio Zaragoza Dorwald, Christine Bruun Schiodt, Thomas Kruse Hansen, Kjeld Madsen
-
Publication number: 20090111857Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.Type: ApplicationFiled: October 24, 2008Publication date: April 30, 2009Applicant: AstraZeneca ABInventors: Peter DOVE, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
-
Publication number: 20090111995Abstract: The present invention relates to a process for the manufacture of an angiotensin receptor blocker (ARB; also called angiotension II receptor antagonist or AT1 receptor antagonist) and salts thereof, to novel intermediates and process steps.Type: ApplicationFiled: December 23, 2008Publication date: April 30, 2009Inventors: Donatienne Denni-Dischert, Hans Hirt, Dan Neville, Gottfried Sedelmeier, Anita Schnyder, Nadine Derrien, Daniel Kaufmann
-
Publication number: 20090111854Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.Type: ApplicationFiled: October 24, 2008Publication date: April 30, 2009Applicant: AstraZeneca ABInventors: Kenneth Granberg, Andreas Wallberg
-
Publication number: 20090111861Abstract: Disclosed is a phthalamide derivative represented by the general formula (I) or a salt thereof, which shows an excellent controlling effect for use as an agricultural or horticultural insecticide alone or in combination with other agricultural or horticultural insecticide, acaricide, nematicide, fungicide, herbicide, plant growth regulator, biopesticide or the like.Type: ApplicationFiled: December 14, 2006Publication date: April 30, 2009Inventors: Hiroto Harayama, Masanori Tohnishi, Shinsuke Fujioka, Akiyuki Suwa
-
Publication number: 20090105321Abstract: The invention is directed to indoline amide derivatives as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: June 8, 2007Publication date: April 23, 2009Inventors: Michael Boyd, John Colucci
-
Publication number: 20090105279Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: April 23, 2009Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu, Zheng-Yu Yang
-
Patent number: 7517896Abstract: The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.Type: GrantFiled: August 8, 2005Date of Patent: April 14, 2009Assignee: Bayer AktiengesellschaftInventors: Cristina Alonso-Alija, Markus Heil, Dietmar Flubacher, Paul Naab, Josef Pernerstorfer, Johannes-Peter Stasch, Frank Wunder, Klaus Dembowsky, Elizabeth Perzborn, Elke Stahl
-
Publication number: 20090093417Abstract: The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: September 5, 2008Publication date: April 9, 2009Inventors: Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Vivek Sasikumar
-
Publication number: 20090093523Abstract: Compounds of the formula: wherein R1, R2, Ar1, Ar2, and n are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.Type: ApplicationFiled: October 1, 2008Publication date: April 9, 2009Inventors: Daisy Joe Du Bois, Todd Richard Elworthy, Hans Maag, Sunil Sahdeo
-
Patent number: 7504516Abstract: The present invention relates to two novel crystalline forms and a novel 1,4-dioxane solvate of candesartan cilexetil, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: March 27, 2003Date of Patent: March 17, 2009Assignee: Hetero Drugs LimitedInventors: Reddy Bandi Parthasaradhi, Reddy Kura Rathnakar, Reddy Rapolu Raji, Reddy Dasari Muralidhara, Reddy Kesireddy Subash Chander
-
Publication number: 20090069397Abstract: The present application describes deuterium-enriched olmesartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 3, 2008Publication date: March 12, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090062286Abstract: The invention relates to SMYD3 methyltransferase (SMYD3), SMYD3 binding pockets or SMYD3-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to SMYD3 methyltransferase protein, complexes of SMYD3 methyltransferase protein, homologues thereof, or SMYD3-like protein or protein complexes.Type: ApplicationFiled: May 5, 2008Publication date: March 5, 2009Inventors: Kenneth William Foreman, Frances E. Park, Lee Arnold
-
Publication number: 20090054506Abstract: Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.Type: ApplicationFiled: March 24, 2006Publication date: February 26, 2009Inventors: Rui Liang, Emma R. Parmee
-
Publication number: 20090042918Abstract: Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R1, R3, Q, X and R4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.Type: ApplicationFiled: October 5, 2006Publication date: February 12, 2009Applicant: EXELIXIS, INC.Inventors: Patrick Kearney, S. David Brown, Elena S. Koltun
-
Publication number: 20090042962Abstract: An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R1 represents a carboxy group or a substituted or unsubstituted nitrogen-containing 5-membered heterocyclic ring; and R2 and R3 may be the same or different and represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group.Type: ApplicationFiled: April 21, 2006Publication date: February 12, 2009Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Keiichi Shibagaki, Shin-ichiro Hirai, Masatsugu Nakamura
-
Publication number: 20090035268Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: August 1, 2007Publication date: February 5, 2009Inventors: Ying Sun, Dong Liu, Yat Sun Or, Zhe Wang
-
Publication number: 20090036505Abstract: The invention discloses imidazole-5-carboxylic acid derivatives, and their preparation methods. The derivatives of the invention are Angiotensin II receptor antagonists with angiotensin II antagonistic activity and antihypertensive activity, and thereby can be used as a therapeutical agent to treat hypertension.Type: ApplicationFiled: July 31, 2006Publication date: February 5, 2009Inventors: Jianhui Guo, Dong An
-
Publication number: 20090029995Abstract: This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.Type: ApplicationFiled: November 29, 2006Publication date: January 29, 2009Applicants: WARNER-LAMBERT COMPANY, WARNER-LAMBERT COMPANY LLCInventors: Amy Mae Bunker, Mark Anthony Morris, Patrick Michael O'Brien, Michael William Wilson
-
Publication number: 20090018344Abstract: The invention relates to process for the preparation of Candesartan cilexetil. More particularly, it relates to the preparation of pure candesartan cilexetil by the deprotection of Trityl candesartan cilexetil with inorganic acids.Type: ApplicationFiled: February 14, 2007Publication date: January 15, 2009Inventors: Seeta Ramajaneyulu Gorantla, Mohan Bandari, Nageshwara Rao Karusala
-
Publication number: 20080318951Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: June 4, 2008Publication date: December 25, 2008Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
-
Publication number: 20080312451Abstract: The invention provides a process for the preparation of a sartan derivative of formula (I) (formula as filed in paper form) (I) wherein the substituents have the meaning indicated in the description, or a pharmaceutically acceptable salt thereof, comprising reacting 2-cyanophenylboronic acid or a derivative thereof with a p-halobenzyl-1H-imidazole derivative of formula (VI), (formula as filed in paper form) (VI) wherein (part of formula as filed in paper form), X, Y, R1 and R2 are as defined above, and Z is I, Br or Cl, in the presence of a transition metal catalyst and an inorganic or organic base.Type: ApplicationFiled: September 20, 2006Publication date: December 18, 2008Applicant: KRKA, d.d. Novo mestoInventors: Miroslav Veverka, Martin Putala, Heinrich Brath, Silvo Zuppancic
-
Patent number: 7465804Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I: wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole ring; and R1 has the values provided herein. The present invention also provides compositions, uses, and methods for use of the compounds, for instance, for treatment of type II diabetes.Type: GrantFiled: May 17, 2006Date of Patent: December 16, 2008Assignee: Amgen Inc.Inventors: Jonathan Houze, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Ying Sun, Yingcai Wang, Liusheng Zhu
-
Publication number: 20080306067Abstract: A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.Type: ApplicationFiled: October 23, 2006Publication date: December 11, 2008Inventors: Klaus Weigand, Thomas Ullrich, Kate Hoeganauer, Philipp Lehr, Rohan Beckwith
-
Publication number: 20080306128Abstract: The present invention relates to sesquihydrate hydrochloride salt of irbesartan and anhydrous hydrochloride salts of irbesartan. Irbesartan used as the starting material for the preparation of the described hydrochlorides of irbesartan can be in any form, e.g. it can be used when contained in a reaction solution, in crude form, in a filtrate containing several solvents, or in anhydrous or any solvated or hydrated form, in amorphous form or any known crystal form or in a mixture thereof.Type: ApplicationFiled: July 29, 2005Publication date: December 11, 2008Inventors: Silvo Zupancic, Matej Smrkolj, Renata Jaske
-
Publication number: 20080300289Abstract: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.Type: ApplicationFiled: November 21, 2006Publication date: December 4, 2008Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip-Arthur Hipskind, Allie Edward Tripp, Guoxin Zhu
-
Publication number: 20080293791Abstract: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.Type: ApplicationFiled: August 5, 2008Publication date: November 27, 2008Inventors: Erwin Marti, Hans Rudolf Oswald, Peter Buhlmayer, Wolfgang Marterer
-
Publication number: 20080281097Abstract: Process for preparing angiotensin II receptor antagonists, in particular irbesartan, protected forms for the preparation thereof, or a pharmaceutically acceptable salt thereof, that comprises the reaction between a biphenylamino derivative and an oxazolone derivative. New intermediates are useful for the preparation of angiotensin II receptor antagonists.Type: ApplicationFiled: August 3, 2006Publication date: November 13, 2008Applicant: FARMAPROJECTS, S. A.Inventor: Jordi Bessa Belmunt
-
Publication number: 20080275096Abstract: Provided is a process for preparing valsartan and precursors thereof.Type: ApplicationFiled: April 28, 2008Publication date: November 6, 2008Inventors: Zvi Harel, Igor Rukhman
-
Publication number: 20080269305Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: April 23, 2008Publication date: October 30, 2008Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
-
Publication number: 20080269228Abstract: The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 26, 2007Publication date: October 30, 2008Inventors: JOEL D. MOORE, ERIC L. ELLIOTT, YAT SUN OR, ZHE WANG
-
Publication number: 20080261959Abstract: This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan.Type: ApplicationFiled: November 21, 2007Publication date: October 23, 2008Inventors: Ashok Kumar, Manmohan Madhavrao Nimbalkar, Priti Jayesh Bhayani, Mukesh Subhodh Jha, Vaibhav Chinubhai Doshi
-
Patent number: 7439261Abstract: A novel process for the preparation of valsartan and novel intermediates useful in the preparation thereof.Type: GrantFiled: November 19, 2004Date of Patent: October 21, 2008Assignee: Dipharma S.p.A.Inventors: Giancarlo Verardo, Paola Geatti, Graziano Castaldi, Nicoletta Toniutti, Pietro Allegrini
-
Publication number: 20080249093Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.Type: ApplicationFiled: December 13, 2004Publication date: October 9, 2008Applicant: MERCK & CO., INC.Inventors: Vincent J. Colandrea, George A. Doherty, Jeffrey J. Hale, Pei Huo, Irene E. Legiec, Leslie Toth, Petr Vachal, Lin Yan
-
Patent number: 7429581Abstract: The present invention is directed to a compound of formula I, in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic effect and is suitable, for example, for the therapy and prophylaxis of a cardio-vascular disorder like a thromboembolic disease or restenosis. It is a reversible inhibitor of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore is directed to a process for the preparation of the compound of formula I, and pharmaceutical preparation comprising it.Type: GrantFiled: December 23, 2003Date of Patent: September 30, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Nazare, Volkmar Wehner, David W. Will, Hans Matter
-
Patent number: 7423012Abstract: The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.Type: GrantFiled: December 2, 2005Date of Patent: September 9, 2008Assignee: AstraZeneca ABInventors: Marcel Linschoten, Magnus Polla